A Phase I clinical study evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of oral ZN-B-2262 alone or in combination with radiotherapy in patients with advanced solid tumors
Latest Information Update: 28 Oct 2024
At a glance
- Drugs ZN B 2262 (Primary)
- Indications Head and neck cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Suzhou Zanrong Pharmaceutical Technology
Most Recent Events
- 28 Jun 2024 New trial record